Our Partnerships

The MDC works in partnership with many academic and biotech industries to supply patented technologies to Oxford researchers. These new technologies are clinically accredited diagnostics, and are a result of partnerships with:

  • Base Genomics – Supplying patented TAPS methylation assays
  • Illumina – Supplying next generation sequencing platform support
  • Oxford Nanopore – Supplying hand-held diagnostic whole genome sequencing technology for applications in Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Acute Lymphocytic Leukaemia and haemoglobinopathies
  • Adaptive Biotech – Only UK site, based within the OMDC in Oxford, licensed to supply of measurable residual disease, T-Cell Receptor and B-Cell Receptor clonality assays
  • Genomics England – Supplying whole genome sequencing technology
  • Oxford Genomics Centre – supplying high-throughput, whole genome & next generation sequencing
  • Mologic – supplying COVID-19 antibody testing technology

We also have access to patented technology, developed in part by the OMDC, which include:

  • Non-invasive Prenatal Testing ® – foetal DNA analysis
  • AlexaPath – imaging of tumour samples in Africa